Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study
Maximilian J. Hochmair, Alessandro Morabito, Desirée Hao, Cheng‐Ta Yang, Ross A. Soo, James Chih‐Hsin Yang, Rasim Gucalp, Balázs Halmos, Angela Märten, Tanja Čufer
Abstract
Aim: Final overall survival (OS) and time on treatment analysis of patients with EGFR mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. Patients & methods: Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. Results: Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7–29.9). Median OS was 37.6 months (90% CI: 35.5–41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. Conclusion: In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with EGFR mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. Clinical Trial Registration: NCT03370770 (ClinicalTrials.gov)